| Literature DB >> 35865714 |
Chengkang Li1, Peter A Paulsen2, Halise Gül Akıllıoğlu1, Søren B Nielsen2, Kasper Engholm-Keller1, Marianne N Lund1,3.
Abstract
Odor-active volatile sulfur compounds are formed in heated food protein systems. In the present study, hydrogen sulfide (H2S) was found to be the most abundant sulfur volatile in whey protein solutions (whey protein isolate [WPI], a whey model system and single whey proteins) by gas chromatography-flame photometric detector (GC-FPD) analysis after heat treatments (60-90 °C for 10 min, 90 °C for 120 min and UHT-like treatment). H2S was detected in WPI after heating at 90 °C for 10 min, and was significantly increased at higher heat load (90 °C for 120 min and the UHT-like treatment). Site-specific LC-MS/MS-based proteomic analysis was conducted, monitoring desulfurization reactions in these protein systems to investigate the mechanism of H2S formation in heated WPI. Cysteine residues from beta-lactoglobulin were found to be responsible for the formation of H2S in heated WPI, presumably via beta-elimination.Entities:
Keywords: Beta-elimination; GC-FPD and LC-MS/MS; Hydrogen sulfide; Volatile sulfur compound; β-lactoglobulin
Year: 2022 PMID: 35865714 PMCID: PMC9294045 DOI: 10.1016/j.fochms.2022.100120
Source DB: PubMed Journal: Food Chem (Oxf) ISSN: 2666-5662
Fig. 1Cys β-Elimination of Protein-Bound Cys Residue (a), Michael Addition between Dehydroalanine (DHA) and Cys Residues (b), and β-Elimination of Protein-Bound Cystine and the Conversion of Persulfide into Cys Residue (c). Adapted with Modifications from (Nashef et al., 1977, Whitaker and Feeney, 1983).
GC-FPD Quantification of H2S (μM) in Heat-Treated Protein and Amino Acid Samples.#.
| Sample | Heat Treatments | ||||
|---|---|---|---|---|---|
| Unheated | 80 °C (10 min) | 90 °C (10 min) | 90 °C (120 min) | UHT-like (160 °C, 160 s) | |
| α-LA | <LOD | NT | <LOD | <LOD | <LOD |
| β-LG | <LOD | 2.0 ± 0.1 *; a | 7.3 ± 0.2 **; c | 15.4 ± 0.7 ***; c | 22.2 ± 1.8 ****; a |
| Whey model | <LOD | 2.9 ± 0.5 *; b | 9.5 ± 0.6 **; d | 18.7 ± 1.0 ***; d | 30.1 ± 3.0 ****; a,b |
| WPI | <LOD | <LOD | 4.0 ± 0.1 *; b | 23.3 ± 0.4 **; e | 38.1 ± 8.6 ***; a,b |
| Concentrated α-LA | <LOD | NT | 1.5 ± 0.2 *; a | 4.0 ± 0.3 *; a | 51.6 ± 17.9 **; c |
| Cys | <LOD | NT | 3.8 ± 0.3b | 10.7 | 44.8 |
| Met | <LOD | NT | <LOD | <LOD | <LOD |
| Mixed amino acid | <LOD | NT | 4.3 ± 0.6 *; b | 11.6 ± 0.8 **; b | NT |
Protein concentrations of samples: α-LA: 2.45 mg/mL (0.17 mM); β-LG: 15.88 mg/mL (0.87 mM); whey model: 2.45 mg/mL (0.17 mM) α-LA + 15.88 mg/mL (0.87 mM) β-LG; WPI: 30 mg/mL and conc. α-LA: 16 mg/mL (1.11 mM). Amino acid concentrations of samples: Cys: 0.69 mg/mL (5.7 mM); Met: 0.54 mg/mL (3.6 mM) and mixed amino acid: 0.69 mg/mL (5.7 mM) Cys + 0.54 mg/mL (3.6 mM) Met. Values in the same row followed by different number of asterisks (*) are significantly different between treatments, and values in the same column followed by different letters are significantly different between samples (one-way ANOVA with a Tukey-Kramer HSD post-hoc test, p < 0.05), tests were conducted with at least two independent replicates, while only one measurement was performed for the values without standard deviation. NT, not tested; LOD = 1.3 µM.
LC-MS/MS Relative Quantification of Peptides-Bound Dehydroalanine (DHA) and Persulfide in Heat-Treated Protein Samples.*.
| Protein | Cys residue | Modification | Sample | Heat Treatment | ||||
|---|---|---|---|---|---|---|---|---|
| Unheated | 80 °C, 10 min | 90 °C, 10 min | 90 °C, 120 min | UHT-like (160 °C, 160 s) | ||||
| α-LA | Cys6 | Persulfide | α-LA | 4.5 ± 0.4 % a | 5.7 ± 0.9 % a | 6.5 ± 0.5 % a,b | 19.3 ± 2.2 % b,c | 100.0 ± 11.7 % f |
| whey model | 14.5 ± 3.8 % a,b,c | 7.0 ± 1.1 % a,b | 13.0 ± 1.5 % a,b | 34.7 ± 4.2 % d | 75.3 ± 13.0 % e | |||
| WPI | ND | 3.7 ± 0.8 % a | 9.9 ± 1.9 % a,b | 26.9 ± 3.3 % c,d | 81.7 ± 8.8 % e | |||
| Cys28 | DHA | α-LA | ND | ND | ND | 9.1 ± 1.6 % a | 100.0 ± 13.3 % b | |
| whey model | ND | ND | ND | ND | ND | |||
| WPI | ND | ND | ND | ND | ND | |||
| Cys61 | DHA | α-LA | 0.2 ± 0.03 % a | 1.4 ± 0.4 % a | 3.2. ± 0.5 % a | 21.1 ± 4.0 % b | 100.0 ± 20.7 % d | |
| whey model | 0.1 ± 0.03 % a | 1.2 ± 0.2 % a | 2.6 ± 0.4 % a | 11.1 ± 1.7 % a,b | 56.0 ± 11.0 % c | |||
| WPI | ND | 1.7 ± 0.3 % a | 3.4 ± 0.6 % a | 12.1 ± 2.0 % a,b | 49.3 ± 10.0 % c | |||
| Persulfide | α-LA | 0.7 ± 0.1 % a | 1.8 ± 0.2 % a | 2.7 ± 0.2 % a | 16.4 ± 1.6 % b | 100.0 ± 11.8 % e | ||
| whey model | 0.9 ± 0.5 % a | 6.4 ± 0.7 % a,b | 7.0 ± 1.1 % a,b | 10.4 ± 1.1 % a,b | 74.4 ± 11.9 % d | |||
| WPI | ND | ND | 1.6 ± 0.4 % a | 6.8 ± 0.7 % a,b | 50.6 ± 9.1 % c | |||
| Cys73/Cys77 | DHA and Alkylation | α-LA | 0.0 ± 0.0 % a | 3.8 ± 0.5 % a,b | 8.3 ± 0.7 % a,b,c | 13.1 ± 1.7 % c | 62.9 ± 6.5 % e | |
| whey model | ND | 0.6 ± 0.1 % a,b | 2.7 ± 0.3 % a,b | 9.3 ± 1.1 % b,c | 100.0 ± 9.6 % f | |||
| WPI | ND | ND | ND | ND | 52.2 ± 10.9 % d | |||
| 2 × DHA | α-LA | 0.1 ± 0.0 % a | 0.2 ± 0.1 % a | 0.5 ± 0.1 % a | 10.6 ± 2.5 % a,b | 100.0 ± 26.8 % d | ||
| whey model | ND | ND | ND | 1.11 ± 0.56 % a | 48.1 ± 12.7 % c | |||
| WPI | ND | ND | ND | ND | 25.5 ± 12.4 % b | |||
| Cys91 | DHA | α-LA | 0.2 ± 0.0 % a | 1.2 ± 0.1 % a | 3.0 ± 0.2 % a,b | 11.5 ± 0.8 % c | 100.0 ± 9.4 % f | |
| whey model | ND | 0.2 ± 0.4 % a | 3.4 ± 0.5 % a,b | 11.9 ± 1.0 % c | 53.8 ± 4.0 % d | |||
| WPI | ND | 0.4 ± 0.6 % a | 3.3 ± 0.2 % a,b | 7.9 ± 2.5 % b,c | 77.5 ± 6.1 % e | |||
| Cys111 | DHA | α-LA | 0.4 ± 0.2 % a | 1.3 ± 0.1 % a,b | 2.2 ± 0.2 % a,b | 10.5 ± 0.7 % b | 100.0 ± 7.7 % d | |
| whey model | ND | 0.7 ± 0.0 % a | 1.6 ± 0.1 % a,b | 6.9 ± 0.5 % a,b | 74.5 ± 10.8 % c | |||
| WPI | ND | 1.0 ± 0.7 % a,b | 1.5 ± 0.1 % a,b | 5.5 ± 0.6 % a,b | 70.3 ± 8.7 % c | |||
| Persulfide | α-LA | 1.3 ± 0.5 % a | 2.40 ± 0.49 % a | 4.2 ± 0.4 % a,b | 17.3 ± 1.4 % b | 100.0 ± 8.7 % d | ||
| whey model | ND | ND | ND | ND | 73.3 ± 11.2 % c | |||
| WPI | ND | ND | ND | ND | 62.7 ± 15.9 % c | |||
| Cys120 | DHA | α-LA | 1.2 ± 0.2 % a | 1.6 ± 0.2 % a | 2.3 ± 0.3 % a | 9.1 ± 1.2 % a,b | 66.6 ± 10.4 % c | |
| whey model | 2.5 ± 0.4 % a | 2.9 ± 0.3 % a,b | 3.7 ± 0.4 % a,b | 12.2 ± 1.9 % b | 61.1 ± 8.3 % c | |||
| WPI | 0.6 ± 0.1 % a | 1.1 ± 0.2 % a | 2.1 ± 0.2 % a | 9.4 ± 1.2 % a,b | 100.0 ± 13.9 % d | |||
| Persulfide | α-LA | 6.8 ± 1.3 % a | 8.1 ± 1.6 % a | 8.5 ± 1.6 % a | 14.7 ± 2.7 % a | 71.2 ± 14.6 % b,c | ||
| whey model | 36.1 ± 12.1 % b | 14.1 ± 2.8 % a | 11.4 ± 2.1 % a | 15.1 ± 3.1 % a | 100.0 ± 25.3 % d | |||
| WPI | 9.9 ± 2.3 % a | 4.8 ± 0.9 % a | 4.7 ± 1.0 % a | 10.6 ± 1.9 % a | 87.3 ± 19.5 % c,d | |||
| β-LG | Cys66 | DHA | β-LG (Glu-C) | ND | 10.0 ± 1.8 % a | 14.9 ± 3.2 % a | 46.3 ± 7.9 % b | 100.0 ± 23.0 % c |
| whey model | ND | 0.3 ± 0.1 % a | 1.8 ± 0.2 % a | 13.9 ± 2.4 % b | 100.0 ± 15.9 % d | |||
| WPI | ND | 0.3 ± 0.2 % a | 2.4 ± 0.3 % a | 14.3 ± 3.4 % b | 68.7 ± 8.3 % c | |||
| Persulfide | β-LG (Glu-C) | 15.2 ± 2.9 % a | 23.2 ± 4.5 % a,b | 29.9 ± 5.6 % a,b | 42.0 ± 8.1 % b | 100.0 ± 26.0 % c | ||
| whey model | ND | ND | ND | ND | ND | |||
| WPI | ND | ND | ND | ND | ND | |||
| Cys106 | DHA | β-LG (Glu-C) | ND | ND | ND | ND | 100.0 ± 39.8 % | |
| whey model | ND | ND | ND | ND | ND | |||
| WPI | ND | ND | ND | ND | ND | |||
| Persulfide | β-LG (Glu-C) | 0.1 ± 0.0 % a | 0.5 ± 0.1 % a | 1.2 ± 0.2 % a | 2.1 ± 0.6 % a | 100.0 ± 19.1 % b | ||
| whey model | ND | ND | ND | ND | ND | |||
| WPI | ND | ND | ND | ND | ND | |||
| Cys119 & Cys121 | DHA and Alkylation | β-LG (Glu-C) | ND | ND | ND | ND | 100.0 ± 24.8 % a | |
| whey model | ND | ND | ND | ND | ND | |||
| WPI | ND | ND | ND | ND | ND | |||
| Cys160 | DHA | β-LG (Glu-C) | 3.4 ± 0.9 % a | 3.9 ± 1.0 % a | 6.1 ± 1.6 % a | 25.2 ± 6.4 % a | 100.0 ± 35.7 % b | |
| whey model | 0.4 ± 0.1 % a | 2.2 ± 0.3 % a | 4.5 ± 0.5 % a | 23.9 ± 1.9 % b | 80.6 ± 11.1 % c | |||
| WPI | 0.4 ± 0.0 % a | 2.2 ± 0.2 % a | 4.3 ± 0.4 % a | 21.6 ± 1.9 % b | 100.0 ± 10.4 % d | |||
| Persulfide | β-LG (Glu-C) | 8.9 ± 2.1 % a | 8.3 ± 2.0 % a | 8.2 ± 1.8 % a | 9.8 ± 2.5 % a | 100.0 ± 30.0 % b | ||
| whey model | 2.9 ± 0.5 % a | 8.5 ± 1.8 % a,b | 11.2 ± 1.7 % a,b | 18.5 ± 1.5 % b | 96.1 ± 14.8 % c | |||
| WPI | ND | 3.1 ± 0.4 % a | 4.2 ± 0.4 % a,b | 14.3 ± 1.2 % a,b | 100.0 ± 11.3 % c | |||
*The results of DHA and persulfide residues are presented as percentage values (the normalized peak area of the DHA- [or persulfide-] containing peptide for a particular treatment divided by the highest normalized peak area of the same residue peptide among all treatments and samples that followed the same digestion process) with their respective standard deviations (SDs) from the non-reduced sample group. Data from β-LG was Glu-C digested, as indicated as “β-LG (Glu-C)”, while all other samples were digested by Lys-C and trypsin. Values from β-LG (Glu-C) in the same modification (row) followed by different letters are significantly different between treatments. Other values from the same modification at the same Cys residue(s) followed by different letters are significantly different between treatments and systems. (One-way ANOVA with a Tukey-Kramer HSD post-hoc test, p < 0.05, n = 3). ND, not detected; Alkylation, Cys carbamidomethylation (+57 Da).
Quantification of Thiol Concentrations (mM) in Heat-Treated Protein Samples.#.
| Samples | Heat Treatments | |||||
|---|---|---|---|---|---|---|
| Unheated | 70 °C, 10 min | 80 °C (10 min) | 90 °C (10 min) | 90 °C (120 min) | UHT-like (160 °C, 160 s) | |
| α-LA | <LOD | NT | <LOD | 0.00 ± 0.01 * | 0.01 ± 0.01 * | 0.02 ± 0.01 ** |
| Conc. a-LA | 0.01 ± 0.01 * | NT | 0.01 ± 0.01 * | 0.01 ± 0.01 * | 0.05 ± 0.01 ** | 0.12 ± 0.01 *** |
| β-LG | 0.78 ± 0.06 ** | 0.77 ± 0.06 ** | 0.75 ± 0.06 ** | 0.73 ± 0.06 **; a,b | 0.48 ± 0.06 *; a | 1.20 ± 0.14 ***; b |
| Whey model | 0.77 ± 0.05 ** | 0.77 ± 0.05 ** | 0.74 ± 0.05 ** | 0.70 ± 0.05 **; a | 0.45 ± 0.05 *; a | 1.07 ± 0.12 ***; a |
| WPI | 0.77 ± 0.06 ** | 0.76 ± 0.06 ** | 0.77 ± 0.06 ** | 0.78 ± 0.06 **; b | 0.60 ± 0.06 *; b | 1.09 ± 0.07 ***; a,b |
Protein concentrations of samples: α-LA: 2.45 mg/mL (0.17 mM); conc. α-LA: 16 mg/mL (1.11 mM); β-LG: 15.88 mg/mL (0.87 mM); whey model: 2.45 mg/mL (0.17 mM) α-LA + 15.88 mg/mL (0.87 mM) β-LG, and WPI: 30 mg/mL. Values in the same row followed by different number of asterisks (*) are significantly different between treatments, and in β-LG-containing samples, values in the same column followed by different letters are significantly different between different β-LG-containing samples (one-way ANOVA with a Tukey-Kramer HSD post-hoc test, p < 0.05, n = 3). NT, not tested. LOD = 0.003 mM.
LC-MS/MS Quantification of LAN (μM) in Heat-Treated Protein Samples after Acid Hydrolysis.#.
| Sample | Heat treatment | ||||
|---|---|---|---|---|---|
| Unheated | 80 °C (10 min) | 90 °C (10 min) | 90 °C (120 min) | UHT-like (160 °C, 160 s) | |
| α-LA | <LOD | <LOD | <LOD | 1.0 | 1.5 |
| β-LG | <LOD | <LOD | <LOD | 3.9 ± 0.5 **; a | 4.2 ± 0.9 **; a |
| Whey model | <LOD | 1.6 ± 0.6 *; a | 2.0 ± 0.4 *; a | 11.8 ± 1.7 **; b | 14.4 ± 2.1 **; b |
| WPI | <LOD | 1.3 ± 0.1 *; a | 2.6 ± 0.6 *; a | 11.5 ± 1.3 **; b | 21.4 ± 5.0 ***; b |
Protein concentrations of each sample: α-LA: 2.45 mg/mL (0.17 mM); β-LG: 15.88 mg/mL (0.87 mM); whey model: 2.45 mg/mL (0.17 mM) α-LA + 15.88 mg/mL (0.87 mM) β-LG, and WPI: 30 mg/mL. Values in the same row followed by different number of asterisks (*) are significantly different between treatments, and values in the same column followed by different letters are significantly different between samples (one-way ANOVA with a Tukey-Kramer HSD post-hoc test, p < 0.05), values of α-LA were obtained from the mixture of five independent heat treatments. LOD = 0.4 μM.
Estimated Extents of Heat-Induced (a) Cystine Disulfide Cleavage (Calculated via Equation 3) and (b) Cys Converted to H2S (Calculated via Equations 1 and 2).*.
| (a) Sample | Heat treatment | |||
|---|---|---|---|---|
| 80 °C (10 min) | 90 °C (10 min) | 90 °C (120 min) | UHT-like (160 °C, 160 s) | |
| α-LA | N/A | 0.10 % | 0.42 % | 1.44 % |
| Conc. α-LA | 0.03 % | 0.09 % | 0.45 % | 1.34 % |
| β-LG | N/A | N/A | N/A | 12.15 % |
| Whey model | N/A | N/A | N/A | 6.13 % |
| WPI | N/A | N/A | N/A | 6.57 % |
*Protein concentrations of each sample: α-LA: 2.45 mg/mL (0.17 mM); conc. α-LA: 16 mg/mL (1.11 mM); β-LG: 15.88 mg/mL (0.87 mM); whey model: 2.45 mg/mL (0.17 mM) α-LA + 15.88 mg/mL (0.87 mM) β-LG, and WPI: 30 mg/mL. N/A, not applicable.